Lipid profile changes after pronounced weight loss induced by bariatric surgery

Clinical Lipidology

Volumn 7, Issue 2, 2012, Pages 163-175

  Al Zoairy, Ramona ^a   Melmer, Andreas ^a   Ress, Claudia ^a   Laimer, Markus ^a   Kaser, Susanne ^a   Ebenbichler, Christoph ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

bariatric surgery; lipid; lipid profile; lipoprotein; metabolism; obesity; weight loss

Indexed keywords

CARRIER PROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL LIPASE;

ARTERIAL WALL THICKNESS; ARTICLE; ATHEROSCLEROSIS; BARIATRIC SURGERY; CARDIOVASCULAR RISK; CAROTID ARTERY; CHOLESTEROL TRANSPORT; DYSLIPIDEMIA; GASTRIC BANDING; HUMAN; HYPERTRIGLYCERIDEMIA; INSULIN RESISTANCE; LIPID ANALYSIS; LIPID METABOLISM; LIPOLYSIS; OBESITY; PRIORITY JOURNAL; RISK REDUCTION; ROUX Y ANASTOMOSIS; STOMACH BYPASS; SURGICAL TECHNIQUE; WEIGHT REDUCTION;

EID: 84860210890     PISSN: 17460875     EISSN: 17584302     Source Type: Journal    
DOI: 10.2217/clp.12.9     Document Type: Article

References (121)

1. Wang YC, Mcpherson K, Marsh T, Gortmaker SL, Brown M. Health and economic burden of the projected obesity trends in the USA and the UK. Lancet 378(9793), 815-825 (2011).
2. Tzotzas T, Evangelou P, Kiortsis DN. Obesity, weight loss and conditional cardiovascular risk factors. Obes. Rev. 12(5), e282-e289 (2011).
3. Adams TD, Gress RE, Smith SC et al. Long-term mortality after gastric bypass surgery. N. Engl. J. Med. 357(8), 753-761 (2007). (Pubitemid 47295642)
4. Sjöström L, Peltonen M, Jacobson P et al. Bariatric surgery and long-term cardiovascular events. JAMA 307(1), 56-65 (2012).
5. Buchwald H. Bariatric surgery for morbid obesity: health implications for patients, health professionals, and third-party payers. J. Am. Coll. Surg. 200(4), 593-604 (2005). (Pubitemid 40432328)
6. Poirier P, Cornier MA, Mazzone T et al. Bariatric surgery and cardiovascular risk factors: a scientifc statement from the American Heart Association. Circulation 123, 1683-1701 (2011).
7. Culnan DM, Cooney RN, Stanley B, Lynch CJ. Apolipoprotein A-IV, a putative satiety/antiatherogenic factor, rises after gastric bypass. Obesity (Silver Spring) 17(1), 46-52 (2009). (Pubitemid 50310534)
8. Eisenberg S. Lipoproteins and lipoprotein metabolism. A dynamic evaluation of the plasma fat transport system. Klin. Wochenschr. 61(3), 119-132 (1983). (Pubitemid 13184664)
9. Zannis VI, Chroni A, Krieger M. Role of ApoA-I, ABCA1, LCAT, and SR-BI in the biogenesis of HDL. J. Mol. Med. 84(4), 276-294 (2006).
10. Morgan J, Carey C, Lincoff A, Capuzzi D. High-density lipoprotein subfractions and risk of coronary artery disease. Curr. Atheroscler. Rep. 6(5), 359-365 (2004). (Pubitemid 39359478)
11. Rothblat GH, Phillips MC. High-density lipoprotein heterogeneity and function in reverse cholesterol transport. Curr. Opin. Lipidol. 21(3), 229-238 (2010).
12. Chan DC, Ng TW, Watts GF. Apolipoprotein A-II: evaluating its signifcance in dyslipidaemia, insulin resistance, and atherosclerosis. Ann. Med. doi: 10.3109/07853 890.2011.573498 (2011) (Epub ahead of print).
13. Boucher J, Ramsamy TA, Braschi S, Sahoo D, Neville TA, Sparks DL. Apolipoprotein A-II regulates HDL stability and affects hepatic lipase association and activity J. Lipid Res. 45(5), 849-858 (2004). (Pubitemid 38552854)
14. Shachter NS. Apolipoproteins C-I and C-III as important modulators of lipoprotein metabolism. Curr. Opin. Lipidol. 12(3), 297-304 (2001). (Pubitemid 32521955)
15. Olivieri O, Martinelli N, Girelli D et al. Apolipoprotein C-III predicts cardiovascular mortality in severe coronary artery disease and is associated with an enhanced plasma thrombin generation. J. Thromb. Haemost. 8(3), 463-471 (2010).
16. De Beer MC, Durbin DM, Cai L et al. Apolipoprotein A-II modulates the binding and selective lipid uptake of reconstituted high density lipoprotein by scavenger receptor BI. J. Biol. Chem. 276(19), 15832-15839 (2001).
17. Thuahnai ST, Lund-Katz S, Dhanasekaran P et al. Scavenger receptor class B type I-mediated cholesteryl ester-selective uptake and effux of unesterifed cholesterol. Infuence of high density lipoprotein size and structure. J. Biol. Chem. 279(13), 12448-12455 (2004). (Pubitemid 38445813)
18. Attia N, Nakbi A, Smaoui M et al. Increased phospholipid transfer protein activity associated with the impaired cellular cholesterol effux in Type 2 diabetic subjects with coronary artery disease. Tohoku J. Exp. Med. 213(2), 129-137 (2007). (Pubitemid 47554873)
19. O'Brien PJ, Alborn WE, Sloan JH et al. The novel apolipoprotein A5 is present in human serum, is associated with VLDL, HDL, and chylomicrons, and circulates at very low concentrations compared with other apolipoproteins. Clin. Chem. 51(2), 351-359 (2005). (Pubitemid 40175805)
20. Havasi V, Szolnoki Z, Talian G et al. Apolipoprotein A5 gene promoter region T-1131C polymorphism associates with elevated circulating triglyceride levels and confers susceptibility for development of ischemic stroke. J. Mol. Neurosci. 29(2), 177-183 (2006). (Pubitemid 44352541)
21. Pennacchio LA, Olivier M, Hubacek JA et al. An apolipoprotein infuencing triglycerides in humans and mice revealed by comparative sequencing. Science 294(5540), 169-173 (2001). (Pubitemid 32952971)
22. Van Der Vliet HN, Schaap FG, Levels JH et al. Adenoviral overexpression of apolipoprotein A-V reduces serum levels of triglycerides and cholesterol in mice. Biochem. Biophys. Res. Commun. 295(5), 1156-1159 (2002).
23. Schaap FG, Rensen PC, Voshol PJ et al. ApoAV reduces plasma triglycerides by inhibiting very low density lipoprotein-triglyceride (VLDL-TG) production and stimulating lipoprotein lipase-mediated VLDL-TG hydrolysis. J. Biol. Chem. 279(27), 27941-27947 (2004). (Pubitemid 38900062)
24. Warden CH, Langner CA, Gordon JI, Taylor BA, McLean JW, Lusis AJ. Tissue-specifc expression, developmental regulation, and chromosomal mapping of the lecithin:cholesterol acyltransferase gene. Evidence for expression in brain and testes as well as liver. J. Biol. Chem. 264, 21573-21581 (1989). (Pubitemid 20028719)
25. Albers JJ, Tollefson JH, Wolfbauer G, Albright RE Jr. Cholesteryl ester transfer protein in human brain. Int. J. Clin. Lab. Res. 21(3), 264-266 (1992).
26. Rousset X, Vaisman B, Amar M, Sethi AA, Remaley AT. Lecithin:cholesterol acyltransferase-from biochemistry to role in cardiovascular disease. Curr. Opin. Endocrinol. Diabetes Obes. 16(2), 163-171 (2009).
27. Zilversmit DB, Hughes LB, Balmer J. Stimulation of cholesterol ester exchange by lipoprotein-free rabbit plasma. Biochim. Biophys. Acta 409(3), 393-398 (1975).
28. Chajek T, Fielding CJ. Isolation and characterization of a human serum cholesteryl ester transfer protein. Proc. Natl Acad. Sci. USA 75(7), 3445-3449 (1978). (Pubitemid 8395089)
29. Deckelbaum RJ, Eisenberg S, Oschry Y, Butbul E, Sharon I, Olivecrona T. Reversible modifcation of human plasma low density lipoproteins toward triglyceride-rich precursors. A mechanism for losing excess cholesterol esters. J. Biol. Chem. 257(11), 6509-6517 (1982). (Pubitemid 12059945)
30. Swenson TL, Brocia RW, Tall AR. Plasma cholesteryl ester transfer protein has binding sites for neutral lipids and phospholipids. J. Biol. Chem. 263(11), 5150-5157 (1988).
31. Glomset JA. The plasma lecithins:cholesterol acyltransferase reaction. J. Lipid Res. 9(2), 155-167 (1968).
32. Tall AR. Plasma cholesteryl ester transfer protein. J. Lipid Res. 34(8), 1255-1274 (1993). (Pubitemid 23230305)
33. Barter PJ, Brewer HB Jr, Chapman MJ, Hennekens CH, Rader DJ, Tall AR. Cholesteryl ester transfer protein: a novel target for raising HDL and inhibiting atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 23(2), 160-167 (2003). (Pubitemid 36231923)
34. Sikorski JA. Oral cholesteryl ester transfer protein (CETP) inhibitors: a potential new approach for treating coronary artery disease. J. Med. Chem. 49(1), 1-22 (2006). (Pubitemid 43077315)
35. Massey JB, Hickson D, She HS et al. Measurement and prediction of the rates of spontaneous transfer of phospholipids between plasma lipoproteins. Biochim. Biophys. Acta 794(2), 274-280 (1984). (Pubitemid 14098832)
36. Ramsamy TA, Neville TA, Chauhan BM, Aggarwal D, Sparks DL. Apolipoprotein A-I regulates lipid hydrolysis by hepatic lipase. J. Biol. Chem. 275(43), 33480-33486 (2000).
37. Boucher JG, Nguyen T, Sparks DL. Lipoprotein electrostatic properties regulate hepatic lipase association and activity. Biochem. Cell Biol. 85(6), 696-708 (2007). (Pubitemid 351198417)
38. 3 for hepatic lipase. Arterioscler. Thromb. Vasc. Biol. 16(6), 755-762 (1996). (Pubitemid 26179364)
39. Mowri HO, Patsch W, Smith LC, Gotto AM Jr, Patsch JR. Different reactivities of high density lipoprotein2 subfractions with hepatic lipase. J. Lipid Res. 33(9), 1269-1279 (1992).
40. Olivecrona T, Bengtsson-Olivecrona G, Ostergaard P, Liu G, Chevreuil O, Hultin M. New aspects on heparin and lipoprotein metabolism. Haemostasis 23(Suppl. 1), 150-160 (1993). (Pubitemid 23116288)
41. Young EK, Chatterjee C, Sparks DL. HDL-ApoE content regulates the displacement of hepatic lipase from cell surface proteoglycans. Am. J. Pathol. 175(1), 448-457 (2009).
42. Hime NJ, Drew KJ, Hahn C, Barter PJ, Rye KA. Apolipoprotein E enhances hepatic lipase-mediated hydrolysis of reconstituted high-density lipoprotein phospholipid and triacylglycerol in an isoform-dependent manner. Biochemistry 43(38), 12306-12314 (2004). (Pubitemid 39280574)
43. Wang H, Eckel RH. Lipoprotein lipase: from gene to obesity. Am. J. Physiol. Endocrinol. Metab. 297(2), E271-E288 (2009).
44. Williams KJ. Molecular processes that handle-and mishandle-dietary lipids. J. Clin. Invest. 118(10), 3247-3259 (2008).
45. Braun JE, Severson DL. Regulation of the synthesis, processing and translocation of lipoprotein lipase. Biochem. J. 287(Pt 2), 337-347 (1992).
46. Goldberg IJ. Lipoprotein lipase and lipolysis: central roles in lipoprotein metabolism and atherogenesis. J. Lipid Res. 37(4), 693-707 (1996). (Pubitemid 26140808)
47. Williams KJ. Some things just have to be done in vivo: GPIHBP1, caloric delivery, and the generation of remnant lipoproteins. Arterioscler. Thromb. Vasc. Biol. 29(6), 792-795 (2009).
48. Sendak RA, Melford K, Kao A, Bensadoun A. Identifcation of the epitope of a monoclonal antibody that inhibits heparin binding of lipoprotein lipase: new evidence for a carboxyl-terminal heparin-binding domain. J. Lipid Res. 39(3), 633-646 (1998). (Pubitemid 28158405)
49. Parthasarathy N, Goldberg IJ, Sivaram P, Mulloy B, Flory DM, Wagner WD. Oligosaccharide sequences of endothelial cell surface heparan sulfate proteoglycan with affnity for lipoprotein lipase. J. Biol. Chem. 269(35), 22391-22396 (1994). (Pubitemid 24282175)
50. Sukonina V, Lookene A, Olivecrona T, Olivecrona G. Angiopoietin-like protein 4 converts lipoprotein lipase to inactive monomers and modulates lipase activity in adipose tissue. Proc. Natl Acad. Sci. USA 103(46), 17450-17455 (2006). (Pubitemid 44788989)
51. Romeo S, Yin W, Kozlitina J et al. Rare loss-of-function mutations in ANGPTL family members contribute to plasma triglyceride levels in humans. J. Clin. Invest. 119(1), 70-79 (2009).
52. Sonnenburg WK, Yu D, Lee EC et al. GPIHBP1 stabilizes lipoprotein lipase and prevents its inhibition by angiopoietin-like 3 and angiopoietin-like 4. J. Lipid Res. 50(12), 2421-2429 (2009).
53. Scuteri A, Najjar SS, Muller DC et al. Metabolic syndrome amplifes the age-associated increases in vascular thickness and stiffness. J. Am. Coll. Cardiol. 43(8), 1388-1395 (2004). (Pubitemid 38496343)
54. Tzou WS, Douglas PS, Srinivasan SR et al. Increased subclinical atherosclerosis in young adults with metabolic syndrome: the Bogalusa Heart Study. J. Am. Coll. Cardiol. 46(3), 457-463 (2005). (Pubitemid 41040286)
55. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of infammation in the prediction of cardiovascular disease in women. N. Engl. J. Med. 342, 836-843 (2000). (Pubitemid 30165206)
56. Mosca L. C-reactive protein-to screen or not to screen? N. Engl. J. Med. 347(20), 1615-1617 (2002).
57. Scanu A. Lipoprotein(a). A genetic risk factor for premature coronary heart disease. JAMA 267(24), 3326-3329 (1992).
58. Clarke R, Peden JF, Hopewell JC et al.; Procardis Consortium. Genetic variants associated with Lp(a) lipoprotein level and coronary disease. N. Engl. J. Med. 361(26), 2518-2528 (2009).
59. Cacciapuoti F. Hyper-homocysteinemia: a novel risk factor or a powerful marker for cardiovascular diseases? Pathogenetic and therapeutical uncertainties. J. Thromb. Thrombolysis 32(1), 82-88 (2011).
60. Aso Y. Plasminogen activator inhibitor (PAI)-1 in vascular infammation and thrombosis. Front. Biosci. 12, 2957-2966 (2007).
61. Tschoner A, Sturm W, Engl J et al. Plasminogen activator inhibitor 1 and visceral obesity during pronounced weight loss after bariatric surgery. Nutr. Metab. Cardiovasc. Dis. 22(4), 340-346 (2012).
62. Pratico D. Prostanoid and isoprostanoid pathways in atherogenesis. Atherosclerosis 201(1), 8-16 (2008).
63. Deigner HP, Hermetter A. Oxidized phospholipids: emerging lipid mediators in pathophysiology. Curr. Opin. Lipidol. 19(3), 289-294 (2008). (Pubitemid 351653568)
64. Wymann MP, Schneiter R. Lipid signalling in disease. Nat. Rev. Mol. Cell Biol. 9(2), 162-176 (2008). (Pubitemid 351158917)
65. Shimizu T. Lipid mediators in health and disease: enzymes and receptors as therapeutic targets for the regulation of immunity and infammation. Annu. Rev. Pharmacol. Toxicol. 49, 123-150 (2009).
66. Cedars A, Jenkins CM, Mancuso DJ, Gross RW. Calcium-independent phospholipases in the heart: mediators of cellular signaling, bioenergetics, and ischemia-induced electrophysiologic dysfunction. J. Cardiovasc. Pharmacol. 53(4), 277-289 (2009).
67. Hamaguchi K, Kuwata H, Yoshihara K et al. Induction of distinct sets of secretory phospholipase A(2) in rodents during infammation. Biochim. Biophys. Acta 1635(1), 37-47 (2003). (Pubitemid 37464994)
68. Jaulmes A, Thierry S, Janvier B, Raymondjean M, Marechal V. Activation of sPLA2-IIA and PGE2 production by high mobility group protein B1 in vascular smooth muscle cells sensitized by IL-1beta. FASEB J. 20(10), 1727-1729 (2006).
69. Thompson A, Gao P, Orfei L et al. Lipoprotein-associated phospholipase A(2) and risk of coronary disease, stroke, and mortality: collaborative ana lysis of 32 prospective studies. Lancet 375(9725), 1536-1544 (2010).
70. Kiortsis DN, Tsouli S, Lourida ES et al. Lack of association between carotid intima-media thickness and PAF-acetylhydrolase mass and activity in patients with primary hyperlipidemia. Angiology 56(4), 451-458 (2005). (Pubitemid 41040531)
71. Després JP, Lamarche B, Mauriège P et al. Hyperinsulinemia as an independent risk factor for ischemic heart disease. N. Engl. J. Med. 334(15), 952-957 (1996). (Pubitemid 26114161)
72. Alberti KG, Zimmet P, Shaw J. The metabolic syndrome-a new worldwide defnition. Lancet 366(9491), 1059-1062 (2005). (Pubitemid 41338752)
73. Vega GL. Management of atherogenic dyslipidemia of the metabolic syndrome: evolving rationale for combined drug therapy. Endocrinol. Metab. Clin. North Am. 33(3), 525-544 (2004). (Pubitemid 38953887)
74. Lamon-Fava S, Wilson PW, Schaefer EJ. Impact of body mass index on coronary heart disease risk factors in men and women. The Framingham Offspring Study. Arterioscler. Thromb. Vasc. Biol. 16(12), 1509-1515 (1996). (Pubitemid 26427605)
75. Arsenault BJ, Boekholdt SM, Kastelein JJ. Lipid parameters for measuring risk of cardiovascular disease. Nat. Rev. Cardiol. 8(4), 197-206 (2011).
76. Ginsberg HN, MacCallum PR. The obesity, metabolic syndrome, and Type 2 diabetes mellitus pandemic: Part I. Increased cardiovascular disease risk and the importance of atherogenic dyslipidemia in persons with the metabolic syndrome and Type 2 diabetes mellitus. J. Cardiometab. Syndr. 4(2), 113-119 (2009).
77. Fisher EA, Ginsberg HN. Complexity in the secretory pathway: the assembly and secretion of apolipoprotein B-containing lipoproteins. J. Biol. Chem. 277(20), 17377-17380 (2002). (Pubitemid 34967535)
78. Ginsberg HN. Insulin resistance and cardiovascular disease. J. Clin. Invest. 106(4), 453-458 (2000). (Pubitemid 30666377)
79. Ginsberg HN, Zhang YL, Hernandez-Ono A. Metabolic syndrome: focus on dyslipidemia. Obesity (Silver Spring) 14(Suppl. 1), S41-S49 (2006).
80. Rashid S, Genest J. Effect of obesity on high-density lipoprotein metabolism. Obesity (Silver Spring) 15(12), 2875-2888 (2007). (Pubitemid 351256646)
81. Uehara Y, Miura S, Von Eckardstein A et al. Unsaturated fatty acids suppress the expression of the ATP-binding cassette transporter G1 (ABCG1) and ABCA1 genes via an LXR/RXR responsive element. Atherosclerosis 191(1), 11-21 (2007). (Pubitemid 46227424)
82. Mauldin JP, Nagelin MH, Wojcik AJ et al. Reduced expression of ATP-binding cassette transporter G1 increases cholesterol accumulation in macrophages of patients with Type 2 diabetes mellitus. Circulation 117(21), 2785-2792 (2008). (Pubitemid 351770459)
83. Attia N, Fournier N, Vedie B et al. Impact of android overweight or obesity and insulin resistance on basal and postprandial SR-BI and ABCA1-mediated serum cholesterol effux capacities. Atherosclerosis 209(2), 422-429 (2010).
84. Hansel B, Giral P, Nobecourt E et al. Metabolic syndrome is associated with elevated oxidative stress and dysfunctional dense high-density lipoprotein particles displaying impaired antioxidative activity. J. Clin. Endocrinol. Metab. 89(10), 4963-4971 (2004). (Pubitemid 39391435)
85. Magkos F, Mohammed BS, Mittendorfer B. Plasma lipid transfer enzymes in non-diabetic lean and obese men and women. Lipids 44(5), 459-464 (2009).
86. Rousset X, Shamburek R, Vaisman B, Amar M, Remaley AT. Lecithin cholesterol acyltransferase: an anti-or pro-atherogenic factor? Curr. Atheroscler. Rep. 13(3), 249-256 (2011).
87. Calabresi L, Franceschini G. Lecithin:cholesterol acyltransferase, high-density lipoproteins, and atheroprotection in humans. Trends Cardiovasc. Med. 20(2), 50-53 (2010).
88. Ebenbichler CF, Laimer M, Kaser S et al. Relationship between cholesteryl ester transfer protein and atherogenic lipoprotein profle in morbidly obese women. Arterioscler. Thromb. Vasc. Biol. 22(9), 1465-1469 (2002).
89. Arai T, Yamashita S, Hirano K et al. Increased plasma cholesteryl ester transfer protein in obese subjects. A possible mechanism for the reduction of serum HDL cholesterol levels in obesity. Arterioscler. Thromb. 14(7), 1129-1136 (1994).
90. Schlitt A, Blankenberg S, Bickel C et al. PLTP activity is a risk factor for subsequent cardiovascular events in CAD patients under statin therapy: the AtheroGene study. J. Lipid Res. 50(4), 723-729 (2009).
91. De Vries R, Groen AK, Perton FG et al. Increased cholesterol effux from cultured fbroblasts to plasma from hypertriglyceridemic Type 2 diabetic patients: roles of pre beta-HDL, phospholipid transfer protein and cholesterol esterifcation. Atherosclerosis 196(2), 733-741 (2008).
92. Tzotzas T, Desrumaux C, Lagrost L. Plasma phospholipid transfer protein (PLTP): review of an emerging cardiometabolic risk factor. Obes. Rev. 10(4), 403-411 (2009).
93. Laimer M W, Engl J, Tschoner A. Effects of weight loss on lipid transfer proteins in morbidly obese women. Lipids 44(12), 1125-1130 (2009).
94. Purnell JQ, Kahn SE, Albers JJ, Nevin DN, Brunzell JD, Schwartz RS. Effect of weight loss with reduction of intra-abdominal fat on lipid metabolism in older men. J. Clin. Endocrinol. Metab. 85(3), 977-982 (2000). (Pubitemid 32269336)
95. Brunzell JD, Zambon A, Deeb SS. The effect of hepatic lipase on coronary artery disease in humans is infuenced by the underlying lipoprotein phenotype. Biochim. Biophys. Acta 1821(3), 365-372 (2012).
96. Zambon S, Romanato G, Sartore G et al. Bariatric surgery improves atherogenic LDL profle by triglyceride reduction. Obes. Surg. 19(2), 190-195 (2009).
97. Mittendorfer B, Patterson BW, Klein S. Effect of weight loss on VLDL-triglyceride and apoB-100 kinetics in women with abdominal obesity. Am. J. Physiol. Endocrinol. Metab. 284(3), E549-E556 (2003). (Pubitemid 36237543)
98. Asztalos BF, Swarbrick MM, Schaefer EJ et al. Effects of weight loss, induced by gastric bypass surgery, on HDL remodeling in obese women. J. Lipid Res. 51(8), 2405-2412 (2010).
99. Lewis GF, Rader DJ. New insights into the regulation of HDL metabolism and reverse cholesterol transport. Circ. Res. 96(12), 1221-1232 (2005). (Pubitemid 40962099)
100. Aron-Wisnewsky J, Julia Z, Poitou C et al. Effect of bariatric surgery-induced weight loss on SR-BI-, ABCG1-, and ABCA1-mediated cellular cholesterol effux in obese women. J. Clin. Endocrinol. Metab. 96(4), 1151-1159 (2011).
101. Harvey SB, Zhang Y, Wilson-Grady J et al. O-glycoside biomarker of apolipoprotein C3: responsiveness to obesity, bariatric surgery, and therapy with metformin, to chronic or severe liver disease and to mortality in severe sepsis and graft vs host disease. J. Proteome Res. 8(2), 603-612 (2009).
102. Ress C, Moschen AR, Sausgruber N et al. The role of apolipoprotein A5 in nonalcoholic fatty liver disease. Gut 60(7), 985-991 (2011).
103. Sjöström L, Lindroos AK, Peltonen M et al. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N. Engl. J. Med. 351(26), 2683-2693 (2004). (Pubitemid 39665322)
104. Sjöström L, Narbro K, Sjöström CD et al. Effects of bariatric surgery on mortality in Swedish obese subjects. N. Engl. J. Med. 357(8), 741-752 (2007). (Pubitemid 47295641)
105. Rother KI, Brown RJ. Selecting weight loss surgery based on HDL genotype-are we there yet? At the brink of 'personalized surgery'. J. Clin. Endocrinol. Metab. 96(6), 1664-1667 (2011).
106. Pardina E, Lecube A, Llamas R et al. Lipoprotein lipase but not hormone-sensitive lipase activities achieve normality after surgically induced weight loss in morbidly obese patients. Obes. Surg. 19(8), 1150-1158 (2009).
107. Kaser S, Laimer M, Sandhofer A, Salzmann K, Ebenbichler CF, Patsch JR. Effects of weight loss on PLTP activity and HDL particle size. Int. J. Obes. Relat. Metab. Disord. 28(10), 1280-1282 (2004). (Pubitemid 39389585)
108. Murdoch SJ, Kahn SE, Albers JJ, Brunzell JD, Purnell JQ. PLTP activity decreases with weight loss: changes in PLTP are associated with changes in subcutaneous fat and FFA but not IAF or insulin sensitivity J. Lipid Res. 44(9), 1705-1712 (2003). (Pubitemid 37185882)
109. Tzotzas T, Dumont L, Triantos A, Karamouzis M, Constantinidis T, Lagrost L. Early decreases in plasma lipid transfer proteins during weight reduction. Obesity (Silver Spring) 14(6), 1038-1045 (2006). (Pubitemid 46219705)
110. Sturm W, Tschoner A, Engl J et al. Effect of bariatric surgery on both functional and structural measures of premature atherosclerosis. Eur. Heart J. 30, 2038-2043 (2009).
111. Habib P, Scrocco JD, Terek M, Vanek V, Mikolich JR. Effects of bariatric surgery on infammatory, functional and structural markers of coronary atherosclerosis. Am. J. Cardiol. 104, 1251-1255 (2009).
112. Hanusch-Enserer U, Zorn G, Wojta J et al. Non-conventional markers of atherosclerosis before and after gastric banding surgery. Eur. Heart J. 30, 1516-1524 (2009).
113. Boman L, Ericson M. Lipoprotein A levels after intestinal bypass operation for morbid obesity. Obes. Surg. 7(2), 125-127 (1997). (Pubitemid 27198865)
114. Pihlajamäki J, Grönlund S, Simonen M et al. Cholesterol absorption decreases after Roux-en-Y gastric bypass but not after gastric banding. Metabolism 59(6), 866-872 (2010).
115. Pohle-Krauza RJ, McCarroll ML, Pasini DD, Dan AG, Zografakis JG. Age and gender exert differential effects on blood lipids in patients after LAGB and LRYGB. Surg. Obes. Relat. Dis. 7(2), 170-175 (2011).
116. Athyros VG, Tziomalos K, Karagiannis A, Mikhailidis DP. Cardiovascular benefts of bariatric surgery in morbidly obese patients. Obes. Rev. 12(7), 515-524 (2011).
117. Brunault P, Jacobi D, Léger J et al. Observations regarding 'quality of life' and 'comfort with food' after bariatric surgery: comparison between laparoscopic adjustable gastric banding and sleeve gastrectomy. Obes. Surg. 21(8), 1225-1231 (2011).
118. Buchwald H, Avidor Y, Braunwald E et al. Bariatric surgery: a systematic review and meta-ana lysis. JAMA 292(14), 1724-1737 (2004). (Pubitemid 39346675)
119. Agren G, Narbro K, Näslund I, Sjöström L, Peltonen M. Long-term effects of weight loss on pharmaceutical costs in obese subjects. A report from the SOS intervention study. Int. J. Obes. Relat. Metab. Disord. 26(2), 184-192 (2002). (Pubitemid 34151195)
120. Sampalis JS, Liberman M, Auger S, Christou NV. The impact of weight reduction surgery on health-care costs in morbidly obese patients. Obes. Surg. 14(7), 939-947 (2004). (Pubitemid 39093468)
121. Zambon S, Romanato G, Sartore G et al. Bariatric surgery improves atherogenic LDL profle by triglyceride reduction. Obes. Surg. 19(2), 190-195 (2009).